F6 FORUM
Organised by WHO Regional Office for Europe, National Institute for Health Disability Insurance (NIHDI), Belgium and Main Association of Austrian Social Security Institutions
The number of new medicines introduced into Europe is increasing, in particular for chronic diseases. National and cross-national medicines policies and strategies are needed to balance demand and expectation for access to high-priced medicines against fiscal responsibility for constrained health budgets.
This forum aims to start the discussion on how to prioritise the introduction of new high-priced medicines, using the area of cancer drugs as an illustrative case study. The forum will also review options for fair pricing to allow availability to all European citizens and affordability for public healthcare systems.
Principles for the appropriate use of medicines and current challenges
Hans Kluge, Director, Health Systems and Public Health, WHO Regional Office for Europe
Medicine prioritisation and new cancer drugs in Europe
Alexandru Eniu, Board Member and Chair of the Emerging Countries Committee, European Society for Medical Oncology (EMSO)
Cancer medicine as a challenge for public pricing and reimbursement
Sabine Vogler, Gesundheit Österreich GmbH, WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies
Understanding patient-side demand for medicines
Nicola Bedlington, Secretary General, European Patients' Forum
Panel discussion
Josef Probst, Director General, Main Association of Austrian Social Security Institutions
Maria Iglesia, Head of Unit for Healthcare Systems, DG Health and Food Safety (DG SANTE), European Commission
Lieven Annemans, Professor of Health Economics, Ghent University, Belgium
Pascale Boulet, Independent Consultant in Medicines Law and Policy
Susan Spillane, Senior Pharmacist, National Centre for Pharmacoeconomics (NCPE), Ireland | Young Forum Gastein Scholar
Moderation
Jack Scannell, Center for the Advancement of Sustainable Medical innovation (CASMI), University of Oxford, UK